Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Current Cardiology Reports
Erschienen in: Current Cardiology Reports 3/2024

28.03.2024 | Congenital Heart Disease (RA Krasuski and G Fleming, Section Editors)

Understanding the Genetic and Non-genetic Interconnections in the Aetiology of Isolated Congenital Heart Disease: An Updated Review: Part 1

verfasst von: Jyoti Maddhesiya, Bhagyalaxmi Mohapatra

Erschienen in: Current Cardiology Reports | Ausgabe 3/2024

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Congenital heart disease (CHD) is the most frequently occurring birth defect. Majority of the earlier reviews focussed on the association of genetic factors with CHD. A few epidemiological studies provide convincing evidence for environmental factors in the causation of CHD. Although the multifactorial theory of gene-environment interaction is the prevailing explanation, explicit understanding of the biological mechanism(s) involved, remains obscure. Nonetheless, integration of all the information into one platform would enable us to better understand the collective risk implicated in CHD development.

Recent Findings

Great strides in novel genomic technologies namely, massive parallel sequencing, whole exome sequencing, multiomics studies supported by system-biology have greatly improved our understanding of the aetiology of CHD. Molecular genetic studies reveal that cardiac specific gene variants in transcription factors or signalling molecules, or structural proteins could cause CHD. Additionally, non-hereditary contributors such as exposure to teratogens, maternal nutrition, parental age and lifestyle factors also contribute to induce CHD. Moreover, DNA methylation and non-coding RNA are also correlated with CHD.

Summary

Here, we inform that a complex combination of genetic, environmental and epigenetic factors interact to interfere with morphogenetic processes of cardiac development leading to CHD. It is important, not only to identify individual genetic and non-inherited risk factors but also to recognize which factors interact mutually, causing cardiac defects.
Literatur
1.
Thomford NE, Dzobo K, Yao NA, Chimusa E, Evans J, Okai E, Kruszka P, Muenke M, Awandare G, Wonkam A, Dandara C. Genomics and epigenomics of congenital heart defects: expert review and lessons learned in Africa. OMICS: A Journal of Integrative Biology. 2018 May 1;22(5):301-21.
2.
Wijnands KP, Zeilmaker GA, Meijer WM, Helbing WA, Steegers-Theunissen RP. Periconceptional parental conditions and perimembranous ventricular septal defects in the offspring. Birth Defects Res A. 2014;100:944–50.CrossRef
3.
Abqari S, Gupta A, Shahab T, Rabbani MU, Ali SM, Firdaus U. Profile and risk factors for congenital heart defects: a study in a tertiary care hospital. Ann Pediatr Cardiol. 2016;9:216.PubMedPubMedCentralCrossRef
4.
Bhardwaj R, Rai SK, Yadav AK, Lakhotia S, Agrawal D, Kumar A, Mohapatra B. Epidemiology of congenital heart disease in India. Congenit Heart Dis. 2015;10:437–46.CrossRef
5.
Chadha SL, Singh N, Shukla DK. Epidemiological study of congenital heart disease. The Indian Journal of Pediatrics. 2001;68:507–10.PubMedCrossRef
6.
7.
8.
Ito S, Chapman KA, Kisling M, John AS. Genetic considerations for adults with congenital heart disease. InAmerican Journal of Medical Genetics Part C: Seminars in Medical Genetics 2020 Mar (Vol. 184, No. 1, pp. 149-153). Hoboken, USA: John Wiley & Sons, Inc.
9.
Russell MW, Chung WK, Kaltman JR, Miller TA. Advances in the understanding of the genetic determinants of congenital heart disease and their impact on clinical outcomes. J Am Heart Assoc. 2018;7: e006906.PubMedPubMedCentralCrossRef
10.
Moore-Morris T, van Vliet PP, Andelfinger G, Puceat M. Role of epigenetics in cardiac development and congenital diseases. Physiol Rev. 2018;98:2453–75.PubMedCrossRef
11.
Obermann‐Borst SA, Vujkovic M, De Vries JH, Wildhagen MF, Looman CW, de Jonge R, Steegers EA, Steegers‐Theunissen RP. A maternal dietary pattern characterised by fish and seafood in association with the risk of congenital heart defects in the offspring. BJOG: an international Journal of Obstetrics & Gynaecology. 2011 Sep;118(10):1205-15.
12.
Wang F, Reece EA, Yang P. Superoxide dismutase 1 overexpression in mice abolishes maternal diabetes–induced endoplasmic reticulum stress in diabetic embryopathy. Am J Obstet Gynecol. 2013;209:345-e1.PubMedCentralCrossRef
13.
Patel SS, Burns TL. Nongenetic risk factors and congenital heart defects. Pediatr Cardiol. 2013;34:1535–55.PubMedCrossRef
14.
Sampayo F, Pinto FF. The sex distribution of congenital cardiopathies. Acta Med Port. 1994;7:413–8.PubMed
15.
Egbe A, Uppu S, Stroustrup A, Lee S, Ho D, Srivastava S. Incidences and sociodemographics of specific congenital heart diseases in the United States of America: an evaluation of hospital discharge diagnoses. Pediatr Cardiol. 2014;35:975–82.PubMedCrossRef
16.
Loffredo CA, Chokkalingam A, Sill AM, Boughman JA, Clark EB, Scheel J, Brenner JI. Prevalence of congenital cardiovascular malformations among relatives of infants with hypoplastic left heart, coarctation of the aorta, and d-transposition of the great arteries. Am J Med Genet A. 2004;124:225–30.CrossRef
17.
Øyen N, Poulsen G, Boyd HA, Wohlfahrt J, Jensen PK, Melbye M. Recurrence of congenital heart defects in families. Circulation. 2009;120:295–301.PubMedCrossRef
18.
Burn J, Brennan P, Little J, Holloway S, Coffey R, Somerville J, Dennis NR, Allan L, Arnold R, Deanfield JE. Recurrence risks in offspring of adults with major heart defects: results from first cohort of British collaborative study. The Lancet. 1998;351:311–6.CrossRef
19.
Blue GM, Kirk EP, Sholler GF, Harvey RP, Winlaw DS. Congenital heart disease: current knowledge about causes and inheritance. Med J Aust. 2012;197:155–9.PubMedCrossRef
20.
Øyen N, Boyd HA, Carstensen L, Søndergaard L, Wohlfahrt J, Melbye M. Risk of congenital heart defects in offspring of affected mothers and fathers. Circulation: Genomic and Precision Medicine. 2022 Aug;15(4):e003533.
21.
Srivastava D. Genetic regulation of cardiogenesis and congenital heart disease. ANNUAL REVIEW OF PATHOLOG. 2006;1:199.CrossRef
22.
Yasuhara J, Garg V. Genetics of congenital heart disease: a narrative review of recent advances and clinical implications. Translational Pediatrics. 2021;10:2366.PubMedPubMedCentralCrossRef
23.
Fahed AC, Gelb BD, Seidman JG, Seidman CE. Genetics of congenital heart disease: the glass half empty. Circ Res. 2013;112:707–20.PubMedCrossRef
24.
Pierpont ME, Brueckner M, Chung WK, Garg V, Lacro RV, McGuire AL, Mital S, Priest JR, Pu WT, Roberts A. Genetic basis for congenital heart disease: revisited: a scientific statement from the American Heart Association. Circulation. 2018;138:e653–711.PubMedPubMedCentralCrossRef
25.
Ellesøe SG, Johansen MM, Bjerre JV, Hjortdal VE, Brunak S, Larsen LA. Familial atrial septal defect and sudden cardiac death: identification of a novel NKX2-5 mutation and a review of the literature. Congenit Heart Dis. 2016;11:283–90.PubMedCrossRef
26.
Dixit R, Narasimhan C, Balekundri VI, Agrawal D, Kumar A, Mohapatra B. Functionally significant, novel GATA4 variants are frequently associated with tetralogy of Fallot. Hum Mutat. 2018;39:1957–72.PubMedCrossRef
27.
Kodo K, Nishizawa T, Furutani M, Arai S, Yamamura E, Joo K, Takahashi T, Matsuoka R, Yamagishi H. GATA6 mutations cause human cardiac outflow tract defects by disrupting semaphorin-plexin signaling. Proc Natl Acad Sci. 2009;106:13933–8.PubMedPubMedCentralCrossRef
28.
Griffin HR, Töpf A, Glen E, Zweier C, Stuart AG, Parsons J, Peart I, Deanfield J, O’Sullivan J, Rauch A. Systematic survey of variants in TBX1 in non-syndromic tetralogy of Fallot identifies a novel 57 base pair deletion that reduces transcriptional activity but finds no evidence for association with common variants. Heart. 2010;96:1651–5.PubMedCrossRef
29.
Zhu J, Fu Y, Nettleton M, Richman A, Han Z. High throughput in vivo functional validation of candidate congenital heart disease genes in Drosophila. Elife. 2017;6: e22617.PubMedPubMedCentralCrossRef
30.
31.
Mohapatra B, Casey B, Li H, Ho-Dawson T, Smith L, Fernbach SD, Molinari L, Niesh SR, Jefferies JL, Craigen WJ. Identification and functional characterization of NODAL rare variants in heterotaxy and isolated cardiovascular malformations. Hum Mol Genet. 2009;18:861–71.PubMedCrossRef
32.
• Yadav ML, Ranjan P, Das P, Jain D, Kumar A, Mohapatra B. Implication of rare genetic variants of NODAL and ACVR1B in congenital heart disease patients from Indian population. Exp Cell Res. 2021;409:112869. This study defined the role of NODAL and ACR1B mutations in impairing the NODAL signaling which might be inducing congenital heart diseases in isolated patients.
33.
Page DJ, Miossec MJ, Williams SG, Monaghan RM, Fotiou E, Cordell HJ, Sutcliffe L, Topf A, Bourgey M, Bourque G. Whole exome sequencing reveals the major genetic contributors to nonsyndromic tetralogy of Fallot. Circ Res. 2019;124:553–63.PubMedPubMedCentralCrossRef
34.
H. Bean LJ, Allen EG, Tinker SW, Hollis ND, Locke AE, Druschel C, Hobbs CA, O’Leary L, Romitti PA, Royle MH,. Lack of maternal folic acid supplementation is associated with heart defects in Down syndrome: a report from the National Down Syndrome Project. Birth Defects Res A. 2011;91:885–93.CrossRef
35.
36.
Soemedi R, Wilson IJ, Bentham J, Darlay R, Töpf A, Zelenika D, Cosgrove C, Setchfield K, Thornborough C, Granados-Riveron J. Contribution of global rare copy-number variants to the risk of sporadic congenital heart disease. The American Journal of Human Genetics. 2012;91:489–501.PubMedCrossRef
37.
Greenway SC, Pereira AC, Lin JC, DePalma SR, Israel SJ, Mesquita SM, Ergul E, Conta JH, Korn JM, McCarroll SA. De novo copy number variants identify new genes and loci in isolated sporadic tetralogy of Fallot. Nat Genet. 2009;41:931–5.PubMedPubMedCentralCrossRef
38.
Kim DS, Kim JH, Burt AA, Crosslin DR, Burnham N, Kim CE, McDonald-McGinn DM, Zackai EH, Nicolson SC, Spray TL. Burden of potentially pathologic copy number variants is higher in children with isolated congenital heart disease and significantly impairs covariate-adjusted transplant-free survival. J Thorac Cardiovasc Surg. 2016;151:1147–51.PubMedCrossRef
39.
Jenkins KJ, Correa A, Feinstein JA, Botto L, Britt AE, Daniels SR, Elixson M, Warnes CA, Webb CL. Noninherited risk factors and congenital cardiovascular defects: current knowledge: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young: endorsed by the American Academy of Pediatrics. Circulation. 2007;115:2995–3014.PubMedCrossRef
40.
Gregg NM. Congenital cataract following German measles in the mother. Problems of Birth Defects: From Hippocrates to Thalidomide and After. 1941:170-80.
41.
Nora JJ. Multifactorial inheritance hypothesis for the etiology of congenital heart diseases: the genetic-environmental interaction. Circulation. 1968;38:604–17.PubMedCrossRef
42.
•• Szot JO, Cuny H, Blue GM, Humphreys DT, Ip E, Harrison K, Sholler GF, Giannoulatou E, Leo P, Duncan EL. A screening approach to identify clinically actionable variants causing congenital heart disease in exome data. Circ Genom Precis Med. 2018;11:e001978. Findings from this study identified clinically actionable variants and additional disease-causal genes, both of which are essential for improving the molecular diagnosis of CHD.
43.
Nicoll R. Environmental contaminants and congenital heart defects: a re-evaluation of the evidence. Int J Environ Res Public Health. 2018;15:2096.PubMedPubMedCentralCrossRef
44.
Nees SN, Chung WK. The genetics of isolated congenital heart disease. InAmerican Journal of Medical Genetics Part C: Seminars in Medical Genetics 2020 Mar (Vol. 184, No. 1, pp. 97-106). Hoboken, USA: John Wiley & Sons, Inc.
45.
Riehle-Colarusso TJ, Patel SS. Maternal nongenetic risk factors for congenital heart defects. InCongenital Heart Disease 2015 (pp. 57-69). Karger Publishers.
46.
Miller A, Riehle-Colarusso T, Siffel C, Frías JL, Correa A. Maternal age and prevalence of isolated congenital heart defects in an urban area of the United States. Am J Med Genet A. 2011;155:2137–45.CrossRef
47.
Liu S, Joseph KS, Lisonkova S, Rouleau J, Van den Hof M, Sauve R, Kramer MS. Association between maternal chronic conditions and congenital heart defects: a population-based cohort study. Circulation. 2013;128:583–9.PubMedCrossRef
48.
Dolk H, McCullough N, Callaghan S, Casey F, Craig B, Given J, Loane M, Lagan BM, Bunting B, Boyle B. Risk factors for congenital heart disease: the Baby Hearts Study, a population-based case-control study. PLoS ONE. 2020;15: e0227908.PubMedPubMedCentralCrossRef
49.
Priest JR, Yang W, Reaven G, Knowles JW, Shaw GM. Maternal midpregnancy glucose levels and risk of congenital heart disease in offspring. JAMA Pediatr. 2015;169:1112–6.PubMedPubMedCentralCrossRef
50.
51.
Leirgul E, Brodwall K, Greve G, Vollset SE, Holmstrøm H, Tell GS, Øyen N. Maternal diabetes, birth weight, and neonatal risk of congenital heart defects in Norway, 1994–2009. Obstet Gynecol. 2016;128:1116–25.PubMedCrossRef
52.
Stover PJ. Physiology of folate and vitamin B 12 in health and disease. Nutr Rev. 2004;62:S3–12.PubMedCrossRef
53.
Botto LD, Mulinare J, Erickson JD. Do multivitamin or folic acid supplements reduce the risk for congenital heart defects? Evidence and gaps. Am J Med Genet A. 2003;121:95–101.CrossRef
54.
Mao B, Qiu J, Zhao N, Shao Y, Dai W, He X, Cui H, Lin X, Lv L, Tang Z. Maternal folic acid supplementation and dietary folate intake and congenital heart defects. PLoS ONE. 2017;12: e0187996.PubMedPubMedCentralCrossRef
55.
Bergström S, Carr H, Petersson G, Stephansson O, Bonamy AK, Dahlström A, Halvorsen CP, Johansson S. Trends in congenital heart defects in infants with Down syndrome. Pediatrics. 2016 Jul 1;138(1).
56.
57.
Stefanovic S, Zaffran S. Mechanisms of retinoic acid signaling during cardiogenesis. Mech Dev. 2017;143:9–19.PubMedCrossRef
58.
Zaffran S, Niederreither K. Retinoic acid signaling and heart development. The Retinoids: Biology, Biochemistry, and Disease. 2015 Mar 20:353-69.
59.
Chazaud C, Chambon P, Dollé P. Retinoic acid is required in the mouse embryo for left-right asymmetry determination and heart morphogenesis. Development. 1999;126:2589–96.PubMedCrossRef
60.
Zile MH, Kostetskii I, Yuan S, Kostetskaia E, Amand TRS, Chen Y, Jiang W. Retinoid signaling is required to complete the vertebrate cardiac left/right asymmetry pathway. Dev Biol. 2000;223:323–38.PubMedCrossRef
61.
Moran R, Robin NH. Congenital heart defects. InEmery and Rimoin's Principles and Practice of Medical Genetics and Genomics 2020 Jan 1 (pp. 3-75). Academic Press.
62.
Watson JN, Seagraves NJ. RNA-Seq analysis in an avian model of maternal phenylketonuria. Mol Genet Metab. 2019;126:23–9.PubMedCrossRef
63.
Malik S, Cleves MA, Honein MA, Romitti PA, Botto LD, Yang S, Hobbs CA, Study NBDP. Maternal smoking and congenital heart defects. Pediatrics. 2008;121:e810–6.CrossRef
64.
Ferencz C, Loffredo CA, Correa-Villasenor A, Wilson PD. Categorization of cardiovascular malformations for risk factor analysis. Genetic and environmental risk factors of cardiac defects. 1997;5:12–28.
65.
Alverson CJ, Strickland MJ, Gilboa SM, Correa A. Maternal smoking and congenital heart defects in the Baltimore-Washington Infant Study. Pediatrics. 2011;127:e647–53.PubMedCrossRef
66.
Oster ME, Riehle-Colarusso T, Correa A. An update on cardiovascular malformations in congenital rubella syndrome. Birth Defects Res A. 2010;88:1–8.CrossRef
67.
Edwards MJ. Hyperthermia and fever during pregnancy. Birth Defects Res A. 2006;76:507–16.CrossRef
68.
Ruffing L. Evalulation of thalidomide children. Birth Defects Orig Artic Ser. 1977;13:287–300.PubMed
69.
Ito T, Ando H, Suzuki T, Ogura T, Hotta K, Imamura Y, Yamaguchi Y, Handa H. Identification of a primary target of thalidomide teratogenicity. science. 2010 Mar 12;327(5971):1345-50.
70.
Donovan KA, An J, Nowak RP, Yuan JC, Fink EC, Berry BC, Ebert BL, Fischer ES. Thalidomide promotes degradation of SALL4, a transcription factor implicated in Duane Radial Ray syndrome. Elife. 2018;7: e38430.PubMedPubMedCentralCrossRef
71.
Matyskiela ME, Couto S, Zheng X, Lu G, Hui J, Stamp K, Drew C, Ren Y, Wang M, Carpenter A. SALL4 mediates teratogenicity as a thalidomide-dependent cereblon substrate. Nat Chem Biol. 2018;14:981–7.PubMedCrossRef
72.
Sakaki-Yumoto M, Kobayashi C, Sato A, Fujimura S, Matsumoto Y, Takasato M, Kodama T, Aburatani H, Asashima M, Yoshida N, Nishinakamura R. The murine homolog of SALL4, a causative gene in Okihiro syndrome, is essential for embryonic stem cell proliferation, and cooperates with Sall1 in anorectal, heart, brain and kidney development.
73.
Patorno E, Huybrechts KF, Bateman BT, Cohen JM, Desai RJ, Mogun H, Cohen LS, Hernandez-Diaz S. Lithium use in pregnancy and the risk of cardiac malformations. N Engl J Med. 2017;376:2245–54.PubMedPubMedCentralCrossRef
74.
Stambolic V, Ruel L, Woodgett JR. Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells. Curr Biol. 1996;6:1664–9.PubMedCrossRef
75.
Ruiz-Villalba A, Hoppler S, van den Hoff MJ. Wnt signaling in the heart fields: variations on a common theme. Dev Dyn. 2016;245:294–306.PubMedCrossRef
76.
Gao S-Y, Wu Q-J, Sun C, Zhang T-N, Shen Z-Q, Liu C-X, Gong T-T, Xu X, Ji C, Huang D-H. Selective serotonin reuptake inhibitor use during early pregnancy and congenital malformations: a systematic review and meta-analysis of cohort studies of more than 9 million births. BMC Med. 2018;16:1–14.CrossRef
77.
Choi D-S, Ward SJ, Messaddeq N, Launay J-M, Maroteaux L. 5-HT2B receptor-mediated serotonin morphogenetic functions in mouse cranial neural crest and myocardiac cells. Development. 1997;124:1745–55.PubMedCrossRef
78.
Cresci M, Foffa I, Ait-Ali L, Pulignani S, Gianicolo EAL, Botto N, Picano E, Andreassi MG. Maternal and paternal environmental risk factors, metabolizing GSTM1 and GSTT1 polymorphisms, and congenital heart disease. Am J Cardiol. 2011;108:1625–31.PubMedCrossRef
79.
Waller DK, Mills JL, Simpson JL, Cunningham GC, Conley MR, Lassman MR, Rhoads GG. Are obese women at higher risk for producing malformed offspring? Am J Obstet Gynecol. 1994;170:541–8.PubMedCrossRef
80.
Guelinckx I, Devlieger R, Beckers K, Vansant G. Maternal obesity: pregnancy complications, gestational weight gain and nutrition. Obes Rev. 2008;9:140–50.PubMedCrossRef
81.
Stothard KJ, Tennant PW, Bell R, Rankin J. Maternal overweight and obesity and the risk of congenital anomalies: a systematic review and meta-analysis. JAMA. 2009;301:636–50.PubMedCrossRef
82.
Liu S, Liu J, Tang J, Ji J, Chen J, Liu C. Environmental risk factors for congenital heart disease in the Shandong Peninsula, China: a hospital-based case–control study. J Epidemiol. 2009;19:122–30.PubMedPubMedCentralCrossRef
83.
Botto LD, Mulinare J, Erickson JD. Occurrence of congenital heart defects in relation to maternal multivitamin use. Am J Epidemiol. 2000;151:878–84.PubMedCrossRef
84.
Ramakrishnan A, Lee LJ, Mitchell LE, Agopian AJ. Maternal hypertension during pregnancy and the risk of congenital heart defects in offspring: a systematic review and meta-analysis. Pediatr Cardiol. 2015;36:1442–51.PubMedPubMedCentralCrossRef
85.
Clark EB. Pathogenetic mechanisms of congenital cardiovascular malformations revisited. InSeminars in perinatology 1996 Dec 1 (Vol. 20, No. 6, pp. 465-472). WB Saunders.
86.
Peng J, Meng Z, Zhou S, Zhou Y, Wu Y, Wang Q, Wang J, Sun K. The non-genetic paternal factors for congenital heart defects: a systematic review and meta-analysis. Clin Cardiol. 2019;42:684–91.PubMedPubMedCentralCrossRef
87.
Snijder CA, Vlot IJ, Burdorf A, Obermann-Borst SA, Helbing WA, Wildhagen MF, Steegers EA, Steegers-Theunissen RP. Congenital heart defects and parental occupational exposure to chemicals. Hum Reprod. 2012;27:1510–7.PubMedCrossRef
88.
Nie ZQ, Ou YQ, Chen JM, Liu XQ, Mai JZ, Gao XM, Wu Y, Zhuang J. Risk factors of congenital heart defects in fetal and infants born from 2004 to 2011 in Guangdong. Zhonghua Xin Xue Guan Bing Za Zhi. 2013;41:704–8.PubMed
89.
Obermann-Borst SA, van Driel LM, Helbing WA, de Jonge R, Wildhagen MF, Steegers EA, Steegers-Theunissen RP. Congenital heart defects and biomarkers of methylation in children: a case–control study. Eur J Clin Invest. 2011;41:143–50.PubMedCrossRef
90.
91.
Sheng W, Qian Y, Zhang P, Wu Y, Wang H, Ma X, Chen L, Ma D, Huang G. Association of promoter methylation statuses of congenital heart defect candidate genes with tetralogy of Fallot. J Transl Med. 2014;12:1–9.CrossRef
92.
Joshi RO, Chellappan S, Kukshal P. Exploring the role of maternal nutritional epigenetics in congenital heart disease. Current Developments in Nutrition. 2020 Nov;4(11):nzaa166.
93.
94.
Zhu C, Yu Z-B, Chen X-H, Ji C-B, Qian L-M, Han S-P. DNA hypermethylation of the NOX5 gene in fetal ventricular septal defect. Exp Ther Med. 2011;2:1011–5.PubMedPubMedCentralCrossRef
95.
Lickert H, Takeuchi JK, Von Both I, Walls JR, McAuliffe F, Lee Adamson S, Mark Henkelman R, Wrana JL, Rossant J, Bruneau BG. Baf60c is essential for function of BAF chromatin remodelling complexes in heart development. Nature. 2004;432:107–12.PubMedCrossRef
96.
Gottlieb PD, Pierce SA, Sims RJ, Yamagishi H, Weihe EK, Harriss JV, Maika SD, Kuziel WA, King HL, Olson EN. Bop encodes a muscle-restricted protein containing MYND and SET domains and is essential for cardiac differentiation and morphogenesis. Nat Genet. 2002;31:25–32.PubMedCrossRef
97.
98.
Van Rooij E, Olson EN. MicroRNAs: powerful new regulators of heart disease and provocative therapeutic targets. J Clin Investig. 2007;117:2369–76.PubMedPubMedCentralCrossRef
99.
Zhao Y, Samal E, Srivastava D. Serum response factor regulates a muscle-specific microRNA that targets Hand2 during cardiogenesis. Nature. 2005;436:214–20.PubMedCrossRef
100.
Zhao Y, Ransom JF, Li A, Vedantham V, von Drehle M, Muth AN, Tsuchihashi T, McManus MT, Schwartz RJ, Srivastava D. Dysregulation of cardiogenesis, cardiac conduction, and cell cycle in mice lacking miRNA-1-2. Cell. 2007;129:303–17.PubMedCrossRef
101.
Wu Y, Ma X-J, Wang H-J, Li W-C, Chen L, Ma D, Huang G-Y. Expression of Cx43-related microRNAs in patients with tetralogy of Fallot. World Journal of Pediatrics. 2014;10:138–44.PubMedCrossRef
102.
Liang D, Xu X, Deng F, Feng J, Zhang H, Liu Y, Zhang Y, Pan L, Liu Y, Zhang D. mi RNA-940 reduction contributes to human tetralogy of Fallot development. J Cell Mol Med. 2014;18:1830–9.PubMedPubMedCentralCrossRef
103.
Sucharov CC, Sucharov J, Karimpour-Fard A, Nunley K, Stauffer BL, Miyamoto SD. Micro-RNA expression in hypoplastic left heart syndrome. J Cardiac Fail. 2015;21:83–8.CrossRef
104.
Li D, Ji L, Liu L, Liu Y, Hou H, Yu K, Sun Q, Zhao Z. Characterization of circulating microRNA expression in patients with a ventricular septal defect. PLoS ONE. 2014;9: e106318.PubMedPubMedCentralCrossRef
105.
Li J, Cao Y, Ma X, Wang H, Zhang J, Luo X, Chen W, Wu Y, Meng Y, Zhang J. Roles of miR-1-1 and miR-181c in ventricular septal defects. Int J Cardiol. 2013;168:1441–6.PubMedCrossRef
106.
Song Y, Higgins H, Guo J, Harrison K, Schultz EN, Hales BJ, Moses EK, Goldblatt J, Pachter N, Zhang G. Clinical significance of circulating microRNAs as markers in detecting and predicting congenital heart defects in children. J Transl Med. 2018;16:1–11.CrossRef
107.
Song H, Sun W, Ye G, Ding X, Liu Z, Zhang S, Xia T, Xiao B, Xi Y, Guo J. Long non-coding RNA expression profile in human gastric cancer and its clinical significances. J Transl Med. 2013;11:1–10.CrossRef
108.
• Jiang C, Ding N, Li J, Jin X, Li L, Pan T, Huo C, Li Y, Xu J, Li X. Landscape of the long non-coding RNA transcriptome in human heart. Brief Bioinform. 2019;20:1812–25. This recent study first showed the global view of lncRNAs in human cardiovascular system based on multiples tissues and sheds light on the role of lncRNAs in carediogensis and cardiac disorders.
109.
Dueñas A, Expósito A, Aranega A, Franco D. The role of non-coding RNA in congenital heart diseases. Journal of cardiovascular development and disease. 2019;6:15.PubMedPubMedCentralCrossRef
110.
Zhu S, Cao L, Zhu J, Kong L, Jin J, Qian L, Zhu C, Hu X, Li M, Guo X. Identification of maternal serum microRNAs as novel non-invasive biomarkers for prenatal detection of fetal congenital heart defects. Clin Chim Acta. 2013;424:66–72.PubMedCrossRef
111.
Gu H, Chen L, Xue J, Huang T, Wei X, Liu D, Ma W, Cao S, Yuan Z. Expression profile of maternal circulating microRNAs as non-invasive biomarkers for prenatal diagnosis of congenital heart defects. Biomed Pharmacother. 2019;109:823–30.PubMedCrossRef
112.
Lin H, McBride KL, Garg V, Zhao MT. Decoding genetics of congenital heart disease using patient-derived induced pluripotent stem cells (iPSCs). Frontiers in Cell and Developmental Biology. 2021 Jan 21;9:630069.
113.
Garg V, Kathiriya IS, Barnes R, Schluterman MK, King IN, Butler CA, Rothrock CR, Eapen RS, Hirayama-Yamada K, Joo K. GATA4 mutations cause human congenital heart defects and reveal an interaction with TBX5. Nature. 2003;424:443–7.PubMedCrossRef
114.
Ang Y-S, Rivas RN, Ribeiro AJ, Srivas R, Rivera J, Stone NR, Pratt K, Mohamed TM, Fu J-D, Spencer CI. Disease model of GATA4 mutation reveals transcription factor cooperativity in human cardiogenesis. Cell. 2016;167:1734–49.PubMedPubMedCentralCrossRef
115.
Hrstka SC, Li X, Nelson TJ, Group WPGP. NOTCH1-dependent nitric oxide signaling deficiency in hypoplastic left heart syndrome revealed through patient-specific phenotypes detected in bioengineered cardiogenesis. Stem Cells. 2017;35:1106–19.CrossRef
116.
Rufaihah AJ, Chen CK, Yap CH, Mattar CN. Mending a broken heart: In vitro, in vivo and in silico models of congenital heart disease. Disease Models & Mechanisms. 2021 Mar 1;14(3):dmm047522.
117.
Miao Y, Tian L, Martin M, Paige SL, Galdos FX, Li J, Klein A, Zhang H, Ma N, Wei Y. Intrinsic endocardial defects contribute to hypoplastic left heart syndrome. Cell Stem Cell. 2020;27:574–89.PubMedPubMedCentralCrossRef
118.
Grunert M, Appelt S, Schönhals S, Mika K, Cui H, Cooper A, Cyganek L, Guan K, Sperling SR. Induced pluripotent stem cells of patients with tetralogy of Fallot reveal transcriptional alterations in cardiomyocyte differentiation. Sci Rep. 2020;10:1–11.CrossRef
119.
Han S, Zhang Y, Meng M, Hou Z, Meng P, Zhao Y, Gao H, Tang J, Liu Z, Yang L. Generation of human iPSC line from a patient with tetralogy of Fallot, YAHKMUi001-A, carrying a mutation in TBX1 gene. Stem Cell Research. 2020;42: 101687.PubMedCrossRef
120.
Mikryukov AA, Mazine A, Wei B, Yang D, Miao Y, Gu M, Keller GM. BMP10 signaling promotes the development of endocardial cells from human pluripotent stem cell-derived cardiovascular progenitors. Cell Stem Cell. 2021;28:96–111.PubMedCrossRef
121.
Jin SC, Homsy J, Zaidi S, Lu Q, Morton S, DePalma SR, Zeng X, Qi H, Chang W, Sierant MC. Contribution of rare inherited and de novo variants in 2,871 congenital heart disease probands. Nat Genet. 2017;49:1593–601.PubMedPubMedCentralCrossRef
122.
Watkins WS, Hernandez EJ, Wesolowski S, Bisgrove BW, Sunderland RT, Lin E, Lemmon G, Demarest BL, Miller TA, Bernstein D. De novo and recessive forms of congenital heart disease have distinct genetic and phenotypic landscapes. Nat Commun. 2019;10:1–12.CrossRef
123.
Zaidi S, Choi M, Wakimoto H, Ma L, Jiang J, Overton JD, Romano-Adesman A, Bjornson RD, Breitbart RE, Brown KK. De novo mutations in histone-modifying genes in congenital heart disease. Nature. 2013;498:220–3.PubMedPubMedCentralCrossRef
124.
Li Y-J, Yang Y-Q. An update on the molecular diagnosis of congenital heart disease: focus on loss-of-function mutations. Expert Rev Mol Diagn. 2017;17:393–401.PubMedCrossRef
125.
Sifrim A, Hitz M-P, Wilsdon A, Breckpot J, Al Turki SH, Thienpont B, McRae J, Fitzgerald TW, Singh T, Swaminathan GJ. Distinct genetic architectures for syndromic and nonsyndromic congenital heart defects identified by exome sequencing. Nat Genet. 2016;48:1060–5.PubMedPubMedCentralCrossRef
126.
Fu F, Li R, Li Y, Nie Z-Q, Lei T, Wang D, Yang X, Han J, Pan M, Zhen L. Whole exome sequencing as a diagnostic adjunct to clinical testing in fetuses with structural abnormalities. Ultrasound Obstet Gynecol. 2018;51:493–502.PubMedCrossRef
127.
Drury S, Williams H, Trump N, Boustred C, GOSGene, Lench N, Scott RH, Chitty LS,. Exome sequencing for prenatal diagnosis of fetuses with sonographic abnormalities. Prenat Diagn. 2015;35:1010–7.PubMedCrossRef
128.
Verma SK, Deshmukh V, Nutter CA, Jaworski E, Jin W, Wadhwa L, Abata J, Ricci M, Lincoln J, Martin JF. Rbfox2 function in RNA metabolism is impaired in hypoplastic left heart syndrome patient hearts. Sci Rep. 2016;6:1–10.CrossRef
129.
Homsy J, Zaidi S, Shen Y, Ware JS, Samocha KE, Karczewski KJ, DePalma SR, McKean D, Wakimoto H, Gorham J. De novo mutations in congenital heart disease with neurodevelopmental and other congenital anomalies. Science. 2015;350:1262–6.PubMedPubMedCentralCrossRef
130.
Liu Y, Chang X, Glessner J, Qu H, Tian L, Li D, Nguyen K, Sleiman PM, Hakonarson H. Association of rare recurrent copy number variants with congenital heart defects based on next-generation sequencing data from family trios. Front Genet. 2019;10:819.PubMedPubMedCentralCrossRef
131.
Wang W, Niu Z, Wang Y, Li Y, Zou H, Yang L, Meng M, Wei C, Li Q, Duan L. Comparative transcriptome analysis of atrial septal defect identifies dysregulated genes during heart septum morphogenesis. Gene. 2016;575:303–12.PubMedCrossRef
132.
Matos-Nieves A, Manivannan S, Majumdar U, McBride KL, White P, Garg V. A multi-omics approach using a mouse model of cardiac malformations for prioritization of human congenital heart disease contributing genes. Frontiers in cardiovascular medicine. 2021;8: 683074.PubMedPubMedCentralCrossRef
133.
Silversides CK, Lionel AC, Costain G, Merico D, Migita O, Liu B, Yuen T, Rickaby J, Thiruvahindrapuram B, Marshall CR, Scherer SW. Rare copy number variations in adults with tetralogy of Fallot implicate novel risk gene pathways.
134.
Tomita-Mitchell A, Mahnke DK, Struble CA, Tuffnell ME, Stamm KD, Hidestrand M, Harris SE, Goetsch MA, Simpson PM, Bick DP. Human gene copy number spectra analysis in congenital heart malformations. Physiol Genomics. 2012;44:518–41.PubMedPubMedCentralCrossRef
Metadaten
Titel
Understanding the Genetic and Non-genetic Interconnections in the Aetiology of Isolated Congenital Heart Disease: An Updated Review: Part 1
verfasst von
Jyoti Maddhesiya
Bhagyalaxmi Mohapatra
Publikationsdatum
28.03.2024
Verlag
Springer US
Erschienen in
Current Cardiology Reports / Ausgabe 3/2024
Print ISSN: 1523-3782
Elektronische ISSN: 1534-3170
DOI
https://doi.org/10.1007/s11886-024-02022-9

Weitere Artikel der Ausgabe 3/2024

Current Cardiology Reports 3/2024 Zur Ausgabe

Heart Failure (HJ Eisen, Section Editor)

Combined Heart Kidney Transplantation Versus Heart Transplant in Patients with Renal Failure: Contemporary Insights and Future Perspectives

Cardiometabolic Disease (DM and CV) (CJ Lavie, Section Editor)

Worth Their Weight? An Update on New and Emerging Pharmacologic Agents for Obesity and Their Potential Role for Persons with Cardiac Conditions

Congenital Heart Disease (RA Krasuski and G Fleming, Section Editors)

Understanding the Genetic and Non-Genetic Interconnections in the Aetiology of Syndromic Congenital Heart Disease: An Updated Review: Part 2

Hypertension (DS Geller and DL Cohen, Section Editors)

Planting the Seed for Blood Pressure Control: The Role of Plant-Based Nutrition in the Management of Hypertension

Myocardial Disease (A Abbate and M Merlo, Section Editors)

Fulminant Myocarditis Temporally Associated with COVID-19 Vaccination

Cardiac Biomarkers (AA Quyyumi, Section Editor)

Lysophosphatidic Acid-Mediated Inflammation at the Heart of Heart Failure

Neu im Fachgebiet Kardiologie

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise